Gocovri (amantadine) drug has been approved for treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
Gocovri is a high dose 274 mg amantadine (equivalent to 340 mg amantadine HCl) taken once-daily at bedtime that delivers consistently high levels of amantadine from the morning and throughout the day when dyskinesia occurs.
Parkinson's disease is a chronic neurodegenerative disorder. It results from a loss of dopamine in the brain and is commonly treated by levodopa and dopaminergic therapies that replace lost dopamine.
Dyskinesia is a consequence of levodopa-based Parkinson's disease treatment and is characterized by involuntary and non-rhythmic movements that are purposeless and unpredictable, which impact the activities of daily living.
Common adverse reactions of Gocovri are: hallucinations, dizziness, dry mouth, peripheral edema, constipation, fall and orthostatic hypotension.
haleplushearty.blogspot.com
No comments:
Post a Comment